
The IMID Forum
Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.
Latest episodes

Mar 6, 2025 • 32min
Discussing PsA: Bimekizumab improves patient-reported outcomes and work productivity
Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on the longer-term impact of bimekizumab on patient-reported outcomes, health-related QoL, and work productivity in patients with active PsA who were bDMARD-naïve or had an inadequate response to TNFis for up to 1 year.

Feb 27, 2025 • 11min
Discussing RA: Baricitinib dose reduction and switching to bDMARDs vs JAKis
Join Professors Iain McInnes, Hans Bijlsma, and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA.
In this episode, they discuss two papers: baricitinib dose reduction in patients with RA achieving sustained disease control and switching to bDMARDs vs cycling among JAKis in patients with RA who are inadequate responders to JAKis.

Feb 27, 2025 • 25min
Discussing axSpA: Long-term safety and efficacy of Bimekizumab results from BE-AGILE & BE-MOBILE 1/2
Join Dr Sofia Ramiro and cohosts Professors Atul Deodhar, Hideto Kameda, and Xenofon Baraliakos for the latest episode of the discussing axSpA podcast on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in axSpA.
In this episode, our faculty discusses two papers both focusing on the long-term safety and efficacy of Bimekizumab in axSpA patients with 5-year results from the BE-AGILE study and its OLE, and the 2-year results from BE-MOBILE 1 and 2.

Feb 6, 2025 • 36min
Author Interview: Professor Denis McGonagle, 2025
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Denis McGonagle, Professor of investigative rheumatology at the NIHR funded Academic Unit for the Musculoskeletal Diseases and Leeds Teaching Hospitals NHS Trust in the UK, as they discuss his recent review ‘Subclinical psoriatic arthritis and disease interception—where are we in 2024?’

Jan 23, 2025 • 11min
Discussing RA: Insights into sustained DMARD-free remission and barriers to CAR T-cell therapy
Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA.
In this episode, Professor McInnes discusses two papers: subgroups of patients with early RA with or without bDMARD who reached sustained DMARD-free remission and barriers to the widespread adoption of CAR T-cell therapy in rheumatic diseases.

Dec 19, 2024 • 24min
Discussing RA: Insights into Filgotinib and Tofacitinib in RA
Join Professor Iain McInnes and Professor Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA.
In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitinib in rheumatoid arthritis.

Dec 19, 2024 • 19min
Discussing AxSpA Podcast: Efficacy and Safety of Upadacitinib
Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenfon Baraliakos to discuss a recent study on the efficacy and safety of upadacitinib in patient with ankylosing spondylitis.

Nov 28, 2024 • 50min
ACR 2024 Review Podcast
Key highlights from the ACR 2024 conference on immune-mediated inflammatory diseases are explored, with a focus on findings related to psoriatic arthritis. The potential of JAK inhibitors, like gazelcomab, is discussed alongside insights into the role of sex differences in medication responses. The impact of central nervous system factors on fatigue in inflammatory diseases is also examined. Emerging treatments like Sonolocumab and advancements in rheumatoid arthritis care are covered, while mental health outcomes related to bimicizumab treatment are analyzed.

Nov 28, 2024 • 31min
Discussing PsA: DISCOVER-2 and BE OPTIMAL/BE COMPLETE post-hoc analyses
Professors discuss groundbreaking studies in Psoriatic Arthritis, focusing on bimekizumab's rapid efficacy for pain and fatigue relief. They delve into long-term results from guselkumab, revealing sustained clinical improvements over two years. The importance of personalized treatment strategies is highlighted, especially concerning the impact of background therapies. They also emphasize patient-reported outcomes, demonstrating how insights into patients' experiences can significantly enhance care and treatment approaches.

Nov 14, 2024 • 19min
Discussing RA: Insights into Filgotinib and Tofacitinib in RA
Join Professor Iain McInnes and Professor Johannes Bijlsma for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA.
In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitinib in rheumatoid arthritis.